Drug Trial Radar · NCT07245953
A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 5, 2025
Primary completion
Feb 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Suzhou HepaThera Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extension period. The main trial phase aims to explore the efficacy of different courses of HT-101 injection combined with HT-102 injection in treating patients with chronic hepatitis B and evaluate the optimal treatment strategy. The extension period phase, based on the main trial, assesses the long-term safety and efficacy of HT-101 injection combined with HT-102 injection.
Conditions
- Chronic Hepatitis B
Interventions
HT-101Drug
HT-101 given by subcutaneous injection
HT-102Drug
HT-102 given by subcutaneous injection
HT-101 placeboDrug
HT-101 placebo given by subcutaneous injection
HT-102 placeboDrug
HT-102 placebo given by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving HBsAg < lower limit of detection (LOD) 0.05 International Unit/mL (IU/mL) and HBV DNA < lower limit of quantitation (LLOQ) with or without anti-HBs seroconversion at W60Time frame: From enrollment to the end of treatment at up to 60 weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
Guangzhou Eighth People's Hospital, Guangzhou Medical University
Guangzhou, Guangdong, China
Nanfang Hospital
Guangzhou, Guangdong, China
Qingyuan People's Hospital
Qingyuan, Guangdong, China
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
Nanning, Guangxi, China
Henan Infectious Diseases Hospital , The Sixth People's Hospital of Zhengzhou
Zhengzhou, Henan, China
The Second Hospital of Nanjing
Nanjing, Jiangsu, China
Zhenjiang Third People's Hospital (Zhenjiang Infectious Diseases Hospital)
Zhenjiang, Jiangsu, China
Nanchang Ninth Hospital
Nanchang, Jiangxi, China
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.